research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
Search
for
Sort by
Research
420-450 / 1000+ results research Paclitaxel/Platinum combination regimen and alopecia
Most patients experienced significant but reversible hair loss during treatment.
research Application of Scaffold-Based Drug Delivery in Oral Cancer Treatment: A Novel Approach
Scaffold-based drug delivery systems improve oral cancer treatment by targeting drugs directly to cancer cells, reducing side effects.
research Hair Disorders Associated with Anticancer Agents
Some cancer treatments cause different types of hair loss, but scalp cooling can help prevent it.
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research AMINOPTERIN IN TREATMENT OF LEUKEMIA IN CHILDREN
Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.
research [Differences in efficacy between drug-eluting beads transbronchial arterial chemoembolization combined with systemic chemotherapy and systemic chemotherapy alone for unresectable lung squamous cell carcinoma].
Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
research ALOPECIA AREATA TREATED WITH THORIUM-X
research ALOPECIA AREATA TREATED WITH THORIUM-X
research Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia
Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Targeted therapy in melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research Monitoring chemotherapy‐induced alopecia with trichoscopy
Chemotherapy caused hair loss with specific patterns, but most patients had hair regrowth after treatment, while some had lasting hair loss.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research The Application Progress of Tumor Microenvironment-Responsive Drug Carriers in Precision Chemotherapy
Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
research Development of Uniform Protocol for Alopecia Areata Clinical Trials
A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
research Minoxidil (Mx) as a prophylaxis of doxorubicin – induced alopecia
Minoxidil not effective in preventing chemotherapy-induced hair loss.
research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
research 213P Photobiomodulation therapy for the management of chemotherapy-induced alopecia: Preliminary results of a randomized, controlled trial
Photobiomodulation therapy may speed up hair regrowth after chemotherapy in the short term.
research Prostate cancer update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Etoposide makes radiation therapy more effective against tumors without major side effects.
research Abstracts from the ASA 40thAnnual Meeting
HNG may help prevent the negative effects of chemotherapy on sperm production and white blood cell counts.
research Abstract P5-21-05: ERALOP study: Post adjuvant FEC - docetaxel chemotherapy for early breast cancer: Hair regrowth in the real life
After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research AVALIAÇÃO IN VITRO DO POTENCIAL CITOTÓXICO DOS ÓLEOS DE ALPINIA SPECIOSA, AGERATUM CONYZOIDES E DYSPHANIA AMBROSIOIDES EM LINHAGEM CELULAR DE CÂNCER DE PRÓSTATA, LINFOMA HISTIOCÍTICO E LEUCEMIA MIELOIDE CRÔNICA
The oils showed potential to kill certain cancer cells, especially from Dysphania ambrosioides.
research Cronkhite-Canada syndrome associated with colon cancer metastatic to liver
A patient with Cronkhite-Canada Syndrome developed colon cancer that spread to the liver, showing the need for regular cancer checks in such patients.
research Keeping Our Eye on the Ball: The American Society of Preventive Oncology in 2009
Cancer prevention is crucial, with a focus on research and improved screening methods.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.